| Detected | Trial | Change |
|---|---|---|
| 2026-06-02 | NCT07459751 A Global Phase II/III Clinical Study to Evaluate the Efficacy and Safety of HLX43… |
overall status: "Enrolling By Invitation" → "Recruiting" |
| 2026-05-30 | NCT06115642 A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX43 in… |
overall status: "Recruiting" → "Enrolling By Invitation" |
| 2026-05-30 | NCT07459751 A Global Phase II/III Clinical Study to Evaluate the Efficacy and Safety of HLX43… |
overall status: "Not Yet Recruiting" → "Enrolling By Invitation" |
| 2026-05-19 | NCT06769113 A Phase II Clinical Study to Evaluate HLX43 in Patients With Recurrent/Metastatic ESCC… |
Enrollment increased: 72 -> 102 participants |
| 2026-05-19 | NCT06769113 A Phase II Clinical Study to Evaluate HLX43 in Patients With Recurrent/Metastatic ESCC… |
Trial arms changed: 3 -> 4 |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 2/3 | |||
| NCT07459751 | A Global Phase II/III Clinical Study to Evaluate the Efficacy and Safety of HLX43… | Advanced or Metastatic Squamous Non-Small Cell Lung Cancer | Recruiting |
| Phase 2 | |||
| NCT06857279 | A Phase II Clinical Study to Evaluate HLX43 in Subjects With Recurrent or Metastatic Head… | Carcinoma of Head and/or Neck | Recruiting |
| NCT06769152 | A Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX43 (Anti-PD-L1 ADC)… | Cervical Cancer | Recruiting |
| NCT06769113 | A Phase II Clinical Study to Evaluate HLX43 in Patients With Recurrent/Metastatic ESCC… | Esophageal Cancer | Recruiting |
| NCT07269782 | A Phase II Study to Evaluate the Efficacy and Safety of HLX43 + Serplulimab as… | Non Small Cell Lung Cancer | Recruiting |
| NCT07459738 | A Phase II Study to Evaluate the Efficacy and Safety of HLX43 in Patients With Hormone… | Hormone Receptor Positive HER-2 Negative Breast Cancer | Not Yet Recruiting |
| Phase 1 | |||
| NCT06115642 | A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX43 in… | Advanced/Metastatic Malignant Solid Tumors | Enrolling by Invitation |